This study aims to test a potential new treatment for IBS using a Gastrointestinal Reprogramming Product (GaRP) that has been designed by Anatara to address the key underlying factors associated with chronic gastrointestinal conditions like IBS.
GaRP is a multi-component, coated complementary medicine that has demonstrated safety and tolerability in Stage 1 of the trial. In Stage 2, the aim is to confirm efficacy of the dose identified in Stage 1.
